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Background: Although many epidemiologic studies have investigated the CYP1A1 MspI gene polymorphisms and
their associations with esophageal cancer (EC), definite conclusions cannot be drawn. To clarify the effects of
CYP1A1 MspI polymorphisms on the risk of EC, a meta-analysis was performed in Chinese population.
Methods: Related studies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge
Service Platform, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) till
October 2014. Pooled ORs and 95% CIs were used to assess the strength of the associations.
Results: A total of 13 studies including 1,519 EC cases and 1,962 controls were involved in this meta-analysis.
Overall, significant association was found between CYP1A1 MspI polymorphism and EC risk when all studies in the
Chinese population pooled into this meta-analysis (C vs. T: OR = 1.25, 95% CI = 1.04 to 1.51; CC + CT vs. TT: OR = 1.35,
95% CI = 1.06 to 1.72; CC vs. TT + CT: OR = 1.35, 95% CI = 1.03 to 1.76). When we performed stratified analyses by
geographical locations, histopathology type, and source of control, significantly increased risks were found in North
China (C vs. T: OR = 1.38, 95% CI = 1.12 to 1.70; CC vs. TT: OR = 1.72, 95% CI = 1.16 to 2.56; CC + CT vs. TT: OR = 1.52,
95% CI = 1.14 to 2.02; CC vs. TT + CT: OR = 1.55, 95% CI = 1.17 to 2.06), in the population-based studies (C vs. T:
OR = 1.22, 95% CI = 1.05 to 1.42; CC vs. TT: OR = 1.38, 95% CI = 1.02 to 1.88; CC + CT vs. TT: OR = 1.36, 95% CI = 1.10
to 1.69; CC vs. TT + CT: OR = 1.43, 95% CI = 1.13 to 1.81) and ESCC (C vs. T: OR = 1.17, 95% CI = 1.04 to 1.32; CC + CT
vs. TT: OR = 1.28, 95% CI = 1.08 to 1.52).
Conclusions: This meta-analysis provides the evidence that CYP1A1 MspI polymorphism may contribute to the EC
development in the Chinese population.
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Background
Esophageal cancer (EC) is the eighth most common can-
cer and sixth most deadly cancer worldwide, with an
estimated 482,300 new esophageal cancer cases and
406,800 deaths in 2008 [1]. Its incidence rates vary inter-
nationally; China and southern and eastern Africa are
the relatively high risk areas [1]. In China, more stri-
kingly, esophageal cancer ranks the fifth most common
diagnosed cancer and fourth leading cause of cancer-* Correspondence: Huizheng2000@126.com
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unless otherwise stated.related mortality [2]. The mechanisms of esophageal car-
cinogenesis have not been fully illustrated. Tobacco use
[3,4], alcohol consumption [3,5], low socioeconomic sta-
tus, poor oral hygiene, and nutritional deficiencies [6-8]
have been identified as risk factors for esophageal can-
cer. Yet, only a subset of individuals exposed to these
risk factors eventually develop esophageal cancer, indi-
cating a pivotal role of genetic factors in the esophageal
carcinogenesis. In recent years, several common low-
penetrance genes have been identified as potential eso-
phageal cancer susceptibility genes. An important one is
cytochrome P450 1A1 (CYP1A1), which plays an essen-
tial role in the metabolic activation of major classes of
tobacco procarcinogen such as aromatic amines andntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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affect the metabolism of the environmental carcinogens
and alter susceptibility to esophageal cancer.
CYP1A1 enzyme is a member of the CYP superfamily
and prone to mutation [9]. Agundez [9] revealed an as-
sociation between CYP1A1 enzyme activity and the risk
of developing several types of cancers, including EC.
CYP1A1 A2455G and T3801C are two most commonly
studied polymorphism loci. CYP1A1 T3801C polymor-
phism (MspI, rs4646903), also known as the m1 allele, is a
substitution of T with C in the non-coding 3′-flanking re-
gion which resulting in a highly inducible activity of the
enzyme [10,11]. The first research of the association be-
tween CYP1A1 MspI polymorphism and EC was reported
by Hori and co-workers in 1997 among the Japan popula-
tion [12]. As a consequence, many studies analyzed the
influence of CYP1A1 MspI polymorphism on EC risk;
however, no clear consensus was reached. Meta-analyses
of studies on the gene in other ethnic groups have
been reported elsewhere and produced conflicting results
[13-15]. In order to lessen the impact of different genetic
background, we performed this meta-analysis to assess the
relationship of CYP1A1 MspI polymorphism with risk of
EC in Chinese population.
Methods
Literature search
A comprehensive literature search was performed using
the PubMed, Springer Link, Ovid, Chinese Wanfang
Data Knowledge Service Platform, Chinese National
Knowledge Infrastructure (CNKI), and Chinese Biology
Medicine (CBM) for relevant articles published with the
following Mesh terms: (‘Esophageal Neoplasms’ [MeSH]
or ‘esophageal cancer’ or ‘esophageal tumor’ or ‘esophageal
carcinoma’ or ‘esophageal squamous cell’ or ‘esophageal
adenocarcinoma’) and (‘P4501A1’ or ‘CYP1A1’) and (China
or Chinese or Taiwan). An upper date limit of 28
December 2014 was applied, and no lower date limit
was used. The search was performed without any re-
strictions on language and focused on studies conducted
in humans. Concurrently, the reference lists of reviews
and retrieved articles were searched manually.
Inclusion/exclusion criteria
For inclusion, the studies must have met the following
criteria: (1) case–control study or cohort study studying
on association between the CYP1A1 MspI polymor-
phisms and EC susceptibility; (2) all patients with the
diagnosis of EC confirmed by pathological or histological
examination; (3) sufficient published data about sample
size, odds ratio (OR), and their 95% confidence interval
(CI); (4) all participants were Chinese; (5) containing
complete information about all genotype frequencies.
Studies were excluded when they were: (1) not case–control study or cohort study; (2) duplicate of previous
publication; (3) based on incomplete data; (4) meta-
analyses, letters, reviews, or editorial articles.
Data extraction
Information was extracted carefully from all eligible
studies independently by two investigators according to
the inclusion criteria listed above. Disagreements were
resolved by discussion. The title and abstract of all po-
tentially relevant articles were screened to determine
their relevance. Full articles were also scrutinized if the
title and abstract were ambiguous. The following data
was collected from each study: first author’s surname,
year of publication, geographical location, histopathology
type, source of control, total numbers of cases and con-
trols, and the numbers of cases and controls who har-
bored the MspI genotypes. If data from any category
were not reported in the primary study, the items were
designated ‘not stated’. We did not contact the author of
the primary study to request the information.
Statistical analysis
Crude odds ratios (ORs) together with their correspon-
ding 95% CIs were used to assess the strength of asso-
ciation between the CYP1A1 MspI polymorphism and
the risk of EC. The pooled ORs were performed for al-
lele model (C vs. T), dominant model (CT + CC vs. TT),
recessive model (CC vs. CT + TT), heterozygous model
(CC vs. CT), and homozygous model (CC vs. TT), re-
spectively. Between-study heterogeneity was assessed by
the Q-statistics with P values <0.1. Dependent on the re-
sults of heterogeneity test among individual studies, the
fixed effect model (Mantel-Haenszel) or random effect
model (DerSimonian and Laird) was selected to sum-
marize the combined OR and their 95% CI. Hardy-
Weinberg equilibrium (HWE) was calculated by using
the goodness-of-fit test, and deviation was considered
when P < 0.05. The significance of the pooled OR was
determined by the z test. Sensitivity analysis was con-
ducted to verify stability of the meta-analysis using both
models (the fixed effect model and random effect model).
Begg’s funnel plots and Egger’s linear regression test were
used to assess publication bias. In addition to the com-
parison among all subjects, we also performed stratifica-
tion analyses by geographical locations, histopathology
type, and source of control. All the statistical analysis was
conducted by using STATA statistical package (version 10,
STATA, College Station, TX, USA).
Results
Eligible studies
Figure 1 graphically illustrates the trial flow chart. A
total of 51 articles regarding CYP1A1 MspI polymor-
phism with respect to EC were identified. After screening
14 full-text articles excluded: 
2 not case-control studies 
1 data not available 
5 reduplicate studies 
6 studies for exon7
21 records excluded: 
5 obviously irrelevant studies 
15 reviews and meta-analyses 
1 study not conducted in Chinese  
51 records identified through 
database searching
27 full-text articles assessed 
for eligibility
48 records after duplicates 
removed 
48 records screened 
13 studies included in 
meta-analysis 
Figure 1 Flow diagram of the literature search.
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they were review articles, duplicates, not Chinese popula-
tion, or irrelevant to the current study. In addition, of
these published articles, 14 articles were excluded for full-
text articles assessing due to case reports, reduplicate
studies, or other polymorphisms of CYP1A1. Finally, 13
studies [16-28] including 1,519 EC cases and 1,962 con-
trols were involved in this meta-analysis according to the
inclusion criteria. The publication year of studies ranged
from 2002 to 2014. Eleven of these studies were written in
Chinese, two studies in English. The characteristics of the
included studies are summarized in Table 1.
Meta-analysis results
Table 2 lists the primary results. Overall, a significantly
elevated risk of EC was associated with two variants









Wu 2002 [16] HB Taiwan ESCC 146
Li 2002 [17] HB Shaxi NS 73
Yin 2005 [18] HB Jiangsu ESCC 106
Zhu 2005 [19] HB Shaxi ESCC + EAC 163
Han 2005 [20] HB Shaxi ESCC 89
Lu 2006 [21] PB Xinjiang ESCC 64
Yin 2010 [22] HB Xinjiang NS 96
Ji 2010 [23] PB Gansu ESCC 189
Gao 2012 [24] PB Ningxia ESCC 40
Huang 2012 [25] PB Guangxi ESCC 98
Zhang 2013 [26] PB Shandong ESCC 138
Yun 2014 [27] PB Henan ESCC 157
Zhang 2011 [28] PB Henan ESCC + EAC 160
PB population-based, HB hospital-based, ESCC esophageal squamous cell carcinomOR = 1.35, 95% CI = 1.06 to 1.72, P = 0.005 for hetero-
geneity; for CC vs. TT and CT: OR = 1.35, 95% CI = 1.03
to 1.76, P = 0.008 for heterogeneity). For the allele C vs.
allele T, the pooled OR was 1.25 (95% CI = 1.04 to 1.51;
P = 0.000 for heterogeneity) (Figure 2). However, there
was significant heterogeneity between studies. Hence,
we then performed subgroup analysis by geographical
locations, histopathology type, and source of control. In
the stratified analysis by geographical locations, signifi-
cantly increased risks were found in the population from
North China (C vs. T: OR = 1.38, 95% CI = 1.12 to 1.70;
CC vs. TT: OR = 1.72, 95% CI = 1.16 to 2.56; CC + CT vs.
TT: OR = 1.52, 95% CI = 1.14 to 2.02; CC vs. TT + CT:
OR = 1.55, 95% CI = 1.17 to 2.06) but not found in the
South. In the stratified analysis by source of controls, sig-
nificantly increased risks were found in the population-
based studies (C vs. T: OR = 1.22, 95% CI = 1.05 to 1.42;
CC vs. TT: OR = 1.38, 95% CI = 1.02 to 1.88; CC + CT vs.
TT: OR = 1.36, 95% CI = 1.10 to 1.69; CC vs. TT + CT:
OR = 1.43, 95% CI = 1.13 to 1.81) but not found in the
hospital-based studies. In the subgroup analysis by his-
topathology type, significantly increased association was
found in esophageal squamous cell carcinoma (ESCC) (C
vs. T: OR = 1.17, 95% CI = 1.04 to 1.32; CC + CT vs. TT:
OR = 1.28, 95% CI = 1.08 to 1.52).
Sensitive analysis and bias diagnosis
In order to compare the difference and evaluate the
sensitivity of the meta-analyses, we used both models
(the fixed effect model and random effect model) to
evaluate the stability of the meta-analysis. All the signifi-
cant results were not materially altered (Table 2). Hence,





TT CT CC TT CT CC χ2 P
344 60 65 21 136 146 62 4.16 0.041
75 20 30 23 37 25 13 4.96 0.026
106 42 54 10 41 49 16 0.05 0.829
166 43 75 45 75 67 24 1.96 0.162
98 25 39 25 47 38 13 1.37 0.241
116 23 28 13 44 56 16 0.07 0.786
174 16 45 35 17 88 69 2.13 0.144
216 49 95 45 70 98 48 1.49 0.222
80 15 17 8 28 41 11 0.43 0.511
100 38 41 19 40 43 17 0.85 0.358
170 34 78 26 59 83 28 0.02 0.896
157 73 72 12 95 50 12 2.11 0.146
160 97 63 128 32 -
a, EAC esophageal adenocarcinoma, NS not stated.





n Random-effect model Fixed-effect model Heterogeneity
OR (95% CI) OR (95% CI) χ2 P
C vs. T Total analysis 12 1.25 (1.04 to 1.51) 1.23 (1.11 to 1.37) 33.46 0.000
PB 6 1.22 (1.05 to 1.42) 1.22 (1.05 to 1.42) 1.49 0.914
HB 6 1.30 (0.90 to 1.90) 1.25 (1.08 to 1.44) 31.93 0.000
ESCC 9 1.18 (1.00 to 1.39) 1.17 (1.04 to 1.32) 14.48 0.070
South China 3 0.93 (0.76 to 1.14) 0.93 (0.76 to 1.14) 0.71 0.702
North China 9 1.38 (1.12 to 1.70) 1.37 (1.21 to 1.55) 22.21 0.005
CC vs. TT Total analysis 12 1.42 (0.99 to 2.04) 1.42 (1.15 to 1.75) 29.24 0.002
PB 6 1.38 (1.02 to 1.88) 1.38 (1.02 to 1.88) 0.45 0.994
HB 6 1.46 (0.70 to 3.04) 1.45 (1.09 to 1.93) 28.75 0.000
ESCC 9 1.29 (0.94 to 1.77) 1.27 (1.00 to 1.62) 12.34 0.137
South China 3 0.82 (0.54 to 1.25) 0.82 (0.54 to 1.24) 1.26 0.531
North China 9 1.72 (1.16 to 2.56) 1.73 (1.35 to 2.22) 18.97 0.015
CC vs. CT Total analysis 12 1.09 (0.89 to 1.33) 1.09 (0.89 to 1.32) 10.90 0.452
PB 6 1.07 (0.80 to 1.43) 1.06 (0.80 to 1.42) 2.93 0.711
HB 6 1.12 (0.78 to 1.59) 1.11 (0.85 to 1.45) 7.94 0.160
ESCC 9 1.01 (0.80 to 1.28) 1.01 (0.80 to 1.28) 7.91 0.442
South China 3 0.80 (0.53 to 1.21) 0.80 (0.53 to 1.21) 1.53 0.464
North China 9 1.19 (0.95 to 1.50) 1.19 (0.95 to 1.50) 6.63 0.577
CC + CT vs. TT Total analysis 12 1.35 (1.06 to 1.72) 1.37 (1.17 to 1.59) 26.54 0.005
PB 6 1.36 (1.10 to 1.69) 1.36 (1.10 to 1.69) 4.10 0.536
HB 6 1.39 (0.86 to 2.23) 1.37 (1.11 to 1.70) 22.44 0.000
ESCC 9 1.28 (1.04 to 1.59) 1.28 (1.08 to 1.52) 11.73 0.164
South China 3 0.97 (0.73 to 1.28) 0.97 (0.73 to 1.28) 0.11 0.947
North China 9 1.52 (1.14 to 2.02) 1.58 (1.32 to 1.89) 18.30 0.019
CC vs. TT + CT Total analysis 13 1.35 (1.03 to 1.76) 1.34 (1.13 to 1.59) 26.94 0.008
PB 7 1.41 (1.06 to 1.89) 1.43 (1.13 to 1.81) 8.26 0.219
HB 6 1.30 (0.79 to 2.14) 1.25 (0.98 to 1.60) 18.16 0.003
ESCC 9 1.14 (0.88 to 1.47) 1.12 (0.90 to 1.40) 10.22 0.250
South China 3 0.82 (0.56 to 1.20) 0.81 (0.56 to 1.19) 1.63 0.443
North China 10 1.55 (1.17 to 2.06) 1.53 (1.26 to 1.86) 17.20 0.046
PB population-based, HB hospital-based, ESCC esophageal squamous cell carcinoma, South China including Taiwan, Jiangsu, and Guangxi; North China including
Shaxi, Xinjiang, Gansu, Ningxia, Shandong, and Henan.
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Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias of literatures. The shape of the
funnel plots did not reveal obvious asymmetry (Figure 3).
Then, the Egger’s test was used to provide statistical evi-
dence of funnel plot symmetry. The Egger’s test indi-
cated that there were no obvious publication bias under
the allele model in overall analyses (t = −0.62, P = 0.550).
Discussion
CYP genes are large families of endoplasmic and cyto-
solic enzymes that catalyze the activation and detoxifica-
tion, respectively, of reactive electrophilic compounds,including many environmental carcinogens (for example,
benzo [a] pyrene). CYP1A1 is a phase I enzyme that
regulates the metabolic activation of major classes of
tobacco procarcinogens, such as aromatic amines and
PAHs [29]. Thus, CYP1A1 may affect the metabolism of
environmental carcinogens and alter the susceptibility to
cancers, including EC. Although many studies analyzing
the research results about the association between
CYP1A1 MspI polymorphism and EC, definite con-
clusions cannot be drawn [13-15]. Therefore, we did
this meta-analysis to estimate the relationship between
CYP1A1 MspI polymorphism and susceptibility to EC
among the Chinese population, in order to lessen the
Figure 2 Forest plot (random-effect model) of lung cancer risk associated with CYP1A1 MspI polymorphism using the allele genetic model.
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analysis involved 13 articles with 1,519 EC cases and 1,962
controls. The results indicated a significant association
between CYP1A1 MspI gene polymorphism and EC risk
in the Chinese population. The sensitivity analysis con-
firmed the reliability and stability of the meta-analysis,
and no publication bias was found among studies by
Egger’s test. Therefore, the findings from our meta-
analysis provide a strong evidence for the associationFigure 3 Begg’s funnel plot of CYP1A1 MspI polymorphism and lungbetween CYP1A1 MspI polymorphism and risk of EC in
the Chinese population. Our results were inconsistent
with a previously published meta-analysis in Chinese,
which indicated that CYP1A1 Ile/Val genetic polymor-
phisms, but not CYP1A1 MspI polymorphisms, are asso-
ciated with an increased digestive tract cancers risk in
Chinese populations [30]. It was also inconsistent with the
findings for Caucasians [13-15,31]. The exact mechanism
for the ethnic discrepancy is uncertain but differences incancer risk under the allele genetic model.
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different populations studied may be important. Ethnically
diverse subjects may have unique cultures and lifestyles
that can contribute to different genetic characteristics and
susceptibility to specific cancers. Also, this inconsistency
may be due to the smaller sample sizes for Chinese used
in previous meta-analyses.
When we performed stratified analyses by geogra-
phical locations, histopathology type, and source of
control, significant association with susceptibility for the
development of EC was found in North China, in ESCC,
and population-based studies; however, it was not found
in South China and hospital-based studies. These can be
influenced by some factors. First, the hospital-based
studies usually have some biases because such controls
may just represent a sample of ill-defined reference
population and may not be representative of the general
population. Second, genetic risk factors for EC in North
and South China are different [32]. Last but not the least,
for the relevant small sample size, only three studies from
South China was included in the meta-analysis. With re-
gard to heterogeneity, some of the factors extracted in this
study were the main source of heterogeneity. But it might
also make attributions for other unknown factors, such as
dietary habits, dinking status, other environmental expo-
sures (passive smoking and cooking oil fume), family his-
tory of cancer, other genetic-related respiratory diseases as
well as other related genetic polymorphisms.
The pathways of carcinogen metabolism are complex,
mediated by the activity of multiple enzymes. The effect
of any single gene might have a limited impact on EC
risk than have so far been anticipated. EC has some
known major environmental determinants other than to-
bacco smoke, and large studies with detailed exposure
information are needed to evaluate reliably any moderate
genetic effects. Otherwise, some limitations should be
acknowledged. Firstly, we did not perform subgroup
analysis on smoking status because of the lack of suffi-
cient data. Another potential limitation was that our re-
sults were based on unadjusted estimates. More precise
analyses can be conducted if individual data were avail-
able, which would allow for the adjustment by other co-
variates including age, sex, race, and other factors.
Finally, heterogeneity can interfere with the interpre-
tation of the results of a meta-analysis. Although we
minimized this likelihood by performing a careful search
of published studies and subgroup analyses, significant
inter-study heterogeneity nevertheless existed in the
comparison of geographical locations. In spite of these
limitations, our meta-analysis still had some advantages.
We obeyed the inclusion and exclusion criteria strictly
to reduce selection bias. A funnel plot and Egger’s linear
regression test was used to assess publication bias. In
addition, the impact of different genetic background waslessened by means of including the studies performed in
the Chinese population only, and the test of the Hardy-
Weinberg equilibrium for distribution of the genotypes
in control groups suggested that there was almost no
significantly different genetic background among the
participants.
Conclusions
In conclusion, our meta-analysis supports that CYP1A1
MspI polymorphism might contribute to individual sus-
ceptibility to EC in the Chinese population. Concerning
EC with multifactorial etiology, to further evaluate gene-
gene and gene-environment interactions on CYP1A1
MspI polymorphism and EC, larger studies in selected
populations with different environmental background or
other risk factors are required. Such studies may even-
tually lead to have a better, comprehensive understanding
of the association between the CYP1A1 MspI polymor-
phism and EC risk.
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